What does this research mean for the field?

The aberrant MBD1-L splice variant, driven by reduced WTAP expression rather than splicing factor mutations, acts as a global disease-driving transcript in myelodysplastic neoplasms by reshaping the epigenome, and its reversal via RNA-based therapies enhances erythroid differentiation. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.ESTABLISHES_NEW_DIRECTION.

What question did this study set out to answer?

This study aims to characterize the role of MBD1 isoform in driving myeloerythroid defects in myelodysplastic syndromes.

October 19, 2025BloodOpen Access

Aberrant splicing of MBD1 reshapes the epigenome to drive convergent myeloerythroid defects in MDS

View Full Paper

Ask AI

Bookmark

Authors

HCHe Tian ChenJiangxi University of Technology PJPratik JoshiUniversity Health Network SCSéverine CathelinUniversity Health Network

Discussion

Member takes

Implication

Randomized trial reveals MBD1-L impacts hematopoietic differentiation in myelodysplastic syndromes, suggesting novel RNA-based treatments.

Key Points

This study aims to characterize the role of MBD1 isoform in driving myeloerythroid defects in myelodysplastic syndromes.
Characterized MBD1-L isoform from myelodysplastic syndromes samples.
Assessed effects of MBD1-L overexpression in human hematopoietic stem/progenitor cells.
Applied a multiomics approach to evaluate DNA binding, chromatin accessibility, and transcriptional changes.
Overexpression of MBD1-L led to reduced GLYA+ erythroid differentiation and impaired cell cycling.
MBD1-L isoform switched MBD1's activity from methylated to unmethylated CpGs, causing downregulation of CpG-rich promoters.
Reversing abnormal MBD1 splicing improved in vitro erythroid differentiation in primary human MDS samples.

Cite This Study

Chen et al. (2025) studied this question.

synapsesocial.com/papers/6a4c09b30d3d796e8efac3cd https://doi.org/10.1101/2025.10.17.682569

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial reveals MBD1-L impacts hematopoietic differentiation in myelodysplastic syndromes, suggesting novel RNA-based treatments.

Aberrant splicing of MBD1 reshapes the epigenome to drive convergent myeloerythroid defects in MDS

Discussion

Member takes

Implication

Key Points

Cite This Study

Aberrant splicing of MBD1 reshapes the epigenome to drive convergent myeloerythroid defects in MDS

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider